A. Di Bacco

发表

Molecular abnormalities in chronic myeloid leukemia: deregulation of cell growth and apoptosis.

S. McKenna, T. Cotter, K. Keeshan, 2000, The oncologist.

Pathway-Based Identification of Biomarkers for Targeted Therapeutics: Personalized Oncology with PI3K Pathway Inhibitors

Theresa Zhang, John Rush, Igor Feldman, 2010, Science Translational Medicine.

The SUMO-Specific Protease SENP5 Is Required for Cell Division

H. Ploegh, A. Di Bacco, G. Gill, 2006, Molecular and Cellular Biology.

p53 expression in K562 cells is associated with caspase‐mediated cleavage of c‐ABL and BCR–ABL protein kinases

T. Cotter, A. Di Bacco, 2002, British journal of haematology.

Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.

A. Hui, T. Zimmerman, Shaji K. Kumar, 2014, Blood.

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.

Michael L. Wang, A. Hui, A. Jakubowiak, 2014, Blood.

Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies

David C. Smith, F. Gao, S. Tirrell, 2015, Investigational New Drugs.

Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma

B. Cheson, A. Hui, A. Di Bacco, 2014, Blood Cancer Journal.

c‐MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide‐dexamethasone in myeloma

D. Esseltine, P. Ganly, J. Keats, 2020, European journal of haematology.

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.

D. Esseltine, P. Ganly, P. Richardson, 2017, Blood.

Clinical benefit of ixazomib plus lenalidomide‐dexamethasone in myeloma patients with non‐canonical NF‐κB pathway activation

P. Richardson, A. Di Bacco, P. Moreau, 2020, European journal of haematology.

The combined evaluation of p53 accumulation and of Ki-67 (MIB1) labelling index provides independent information on overall survival of ovarian carcinoma patients.

G. Viale, A. Di Bacco, P. Maisonneuve, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1

P. Richardson, H. van de Velde, A. Di Bacco, 2017, Haematologica.

SUMO-Specific Proteases and the Cell Cycle

A. Di Bacco, G. Gill, 2006, Cell cycle.

Tumour growth fraction and apoptosis in salivary gland acinic cell carcinomas. Prognostic implications of Ki‐67 and bcl‐2 expression and of in situ end labelling (TUNEL)

G. Viale, A. Di Bacco, H. Hellquist, 1997, The Journal of pathology.

FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival.

Cem Elbi, K. Kunii, A. Di Bacco, 2008, Cancer research.

PDK1 attenuation fails to prevent tumor formation in PTEN-deficient transgenic mouse models.

K. Kunii, R. Bronson, M. Scott, 2011, Cancer research.

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.

Bin Li, Matthew Schu, R. Neuwirth, 2014, Blood.

Rapid isolation of cDNA clones by aliquot testing via PCR amplification.

A. Di Bacco, P. Vezzoni, I. Zucchi, 1994, PCR methods and applications.

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

A. Palumbo, A. Hui, P. Ganly, 2016, The New England journal of medicine.

Mapping of the MYCL2 processed gene to Xq22‐23 and identification of an additional L MYC‐related sequence in Xq27.2

A. Pizzuti, A. Di Bacco, C. Montagna, 1999, FEBS letters.

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.

Neeraj Gupta, Eileen Liao, Parameswaran Hari, 2014, The Lancet. Oncology.

Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration

Trevor J Pugh, T. Pugh, D. Auclair, 2021, Clinical Cancer Research.

A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma

S. Lonial, R. Hájek, A. Di Bacco, 2018, Haematologica.

Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas

G. Viale, A. Di Bacco, P. Boracchi, 1996, International journal of cancer.

Angiogenesis in primary lung cancer and lung secondaries.

A. Nicholson, A. Harris, U. Pastorino, 1996, European journal of cancer.

The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications

Trevor J Pugh, Michael D. Robbins, T. Pugh, 2017, Clinical Cancer Research.

The crystal structure of CREG, a secreted glycoprotein involved in cellular growth and differentiation.

A. Di Bacco, G. Gill, M. Cygler, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Tumour growth fraction and apoptosis in salivary gland acinic cell carcinomas. Prognostic implications of Ki‐67 and bcl‐2 expression and of in situ end labelling (TUNEL)

G. Viale, A. Di Bacco, H. Hellquist, 1997, The Journal of pathology.

Pathway-Based Identification of Biomarkers for Targeted Therapeutics: Personalized Oncology with PI3K Pathway Inhibitors

C. Paweletz, I. Feldman, J. Rush, 2010, Science Translational Medicine.

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.

Michael L. Wang, A. Hui, A. Jakubowiak, 2014, Blood.